La danesa se adelanta unos meses a su rival Eli Lilly, que busca luz verde para un medicamento similar

The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.

It marks a first in this new era of weight-loss medications with Wegovy being the only so far to gain approval for a pill version of their shot.